Lipid nucleotide analog prodrugs for oral administration

Details Lipid nucleotide analog prodrugs for oral administration Lipid nucleotide analog prodrugs for oral administration

1995-06-07

1998-10-27

Wilson, James O.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 43, 514 45, 514 46, 514 48, 514 49, 514 50, 514 51, 514885, 536 267, 536 268, 536117, 536118, 536119, A61K 3170

Patent

active

058278311

ABSTRACT:
The oral delivery of many classes of drugs is facilitated by converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn- glycero-3-phosphate derivatives. The method confers the ability to be absorbed through the digestive tract to drugs that are not orally bioavailable in the non-derivatized state, and enhances the effectiveness of drugs that are poorly absorbed or rapidly eliminated. The method provides orally bioavailable lipid prodrugs of pharmaceutical compounds having diverse physiological activities, including anticancer and antiviral agents, anti-inflammatory agents, antihypertensives and antibiotics. Potency of the lipid prodrugs is comparable to that of the corresponding non-derivatized drugs.

REFERENCES:
patent: 4046114 (1977-09-01), Hallgren et al.
patent: 4291024 (1981-09-01), Turcotte et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4534899 (1985-08-01), Sears
patent: 4634719 (1987-01-01), Takaishi et al.
patent: 4810697 (1989-03-01), Speiser et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5071839 (1991-12-01), Liu
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5194635 (1993-03-01), Kingston et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5296506 (1994-03-01), Kingston et al.
patent: 5352806 (1994-10-01), Gunawavdana et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
Dietrich et al. Enhancement of host resistance against virus infections . . . Int. J. Immunopharmacol . . . 8:931-942, 1986.
Dixon, R. et al., AICA-Riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J. Clin. Pharmacol., 31:342-347, 1991.
Hong et al. 1-.beta.-D-Arabinofuranosylcytosine conjugates of ether . . . Lipids, 26:12-1437-1444, 1991.
Hong et al., 79th Annual meeting of the american association for cancer research, vol. 29, p. 359, 1988.
Hostetler et al. Synthesis and antiretroviral activity of phospholipid analogs of axidothymidine and other antiviral nucleosides. The Journal of Biological Chemistry 265:11 :6112-6117, 1990.
Hostetler et al. Phosphatidylazidothymidine. The Journal of Biological Chemistry, 266:18:11714-11717, 1990.
Hostetler et al. Greatly enhanced inhibition of human immunodeficiency, Antimicrob. Agents Chemother., 36:9:2025, 1992.
Larder, B. A. et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy, Science 243:1731-1734, 1989.
Ruprecht, R. M. et al. Supression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine, Nature 323:467-469, 1986.
Ryu et al. Phospholipid-nucleoside conjugates. 3..sup.1 synthesis and preliminary . . . J. Med. Chem. 25:1322-1329, 1982.
Berdel et al. (1987) Lipids 22:943-46.
MacCoss et al. (1978) Biochim. Biophys. Res. Commun. 85:714-23.
Matsushita et al. (1981) Cancer Res. 41:2707-13.
Turcotte et al. (1980) Biochim. Biophys. Acta 619:604-618.
Straubinger et al. (Sep. 23-24, 1992) 2nd National Cancer Inst. Workshop on Taxol & Taxus.
Urata et al. (1989) Jpn. J. Allergol. 38(3):285-95.
Yamaguchi et al. (1987) J. Biol. Chem. 262(7):3369-75.
Fhao et al. (1991) J. Nat. Products 45(6):1607-11.
Yeh et al. (1987) Biochim. Bipohys. Acta 937:315-323.
Nath et al. (1981) J. Cell Biol. 91:232-39.
May et al. (1985) J. Biol. Chem. 260(16):9419-26.
Alkan et al. (abstract) (1991) Pharmaceut. Res. 8(10).
Deutsch et al. (1989) J. Med. Chem. 32:788-92.
Mathew et al. (1992) J. Med. Chem. 35:145-151.
Hiller (1991) Science 253:1095-96.

Affiliated with

Also associated with

Rating

Lipid nucleotide analog prodrugs for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipid nucleotide analog prodrugs for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid nucleotide analog prodrugs for oral administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1613955